Market Highlights: Inflammatory bowel disease (IBD) describes a group of disorders which are caused due to the inflammation of the intestine. Various symptoms of IBD are diarrhea, blood or mucus in stool, fever, abdominal pain, and others. In order to diagnose IBD, various tests such as C - reactive protein (CPR), Complete Blood Count (CBC), and calprotectin test are performed. The market study is being classified by Type (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs) and Corticosteroids), by Application (Hospital and Drugs Stores) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Key Players: The prominent players in the Inflammatory Bowel Disease are AbbVie (United States), Janssen Biotech(United States), Sanofi (France), Takeda Pharmaceuticals (Japan), Bayer AG (Germany), Bristol-Myers Squibb (United States), Eli Lilly and Co. (United States), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (United Kingdom) and Pfizer Inc. (United States).
Major Market Development Highlights In January 2019 Generex Biotechnology Completes acquisition of 51% of Regentys™ Corporation. a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. The Regentys™ Extracellular Matrix Hydrogel (“ECMH”) is a first-in-class, non-pharmacologic, non-surgical treatment option for patients suffering from Ulcerative Colitis. In July 2020 Takeda Japan-based pharma company launches vedolizumab to treat patients with ulcerative colitis & Crohn's disease. GI is Takeda's second therapeutic area in India after rare diseases. The drug is priced at Rs. 71,310 per vial in India. The recommended dose regimen of Kynteles is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter in both UC and CD.
Key Questions Answered in the Report What will the Inflammatory Bowel Disease Market size and the growth rate be in Future? What are the key factors driving the Inflammatory Bowel Disease Market? What are the key market trends and macro-economic impacting the growth of the Inflammatory Bowel Disease Market? What are the challenges to market growth? Who are the key vendors in the Inflammatory Bowel Disease Market? What are the market opportunities and threats faced by the vendors in the Inflammatory Bowel Disease Market? Trending factors influencing the market shares of the Players. What are the key outcomes of the five forces analysis of the Inflammatory Bowel Disease Market?
Research Methodology: The top-down and bottom-up approaches are used to estimate and validate the size of the Global Inflammatory Bowel Disease market. In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Inflammatory Bowel Disease market. In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc. Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Inflammatory Bowel Disease Drugs Manufacturer, Government Regulatory and Research Organizations and End-Use Industry. This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth etc. Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.